Submitted by Anonymous (not verified) on 24 June 2025 - 16:21
Opinion/decision on a Paediatric investigation plan (PIP): Uplizna, Inebilizumab, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Immune system disorders;Surgical and medical procedures, PIP number: P/0217/2024
Source: